Russell Investments Group’s Palvella Therapeutics PVLA Stock Holding History

Russell Investments Group’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.41M	Buy	22,345 +8,818	+65%	+$1.07M	﹤0.01%	1758
2026 Q1	$1.69M	Buy	13,527 +12,298	+1,001%	+$1.28M	﹤0.01%	1959
2025 Q4	$129K	Buy	1,229 +661	+116%	+$56.4K	﹤0.01%	2971
2025 Q3	$35.6K	Buy	+568	New	+$25.3K	﹤0.01%	3409
2021 Q2	–	Sell	-23	Closed	-$4K	–	3308
2021 Q1	$4K	Sell	23 -1,031	-98%	-$225K	﹤0.01%	3081
2020 Q4	$210K	Sell	1,054 -2,304	-69%	-$479K	﹤0.01%	2745
2020 Q3	$555K	Buy	3,358 +3,105	+1,227%	+$707K	﹤0.01%	2345
2020 Q2	$62K	Hold	253	–	–	﹤0.01%	2961
2020 Q1	$45K	Buy	+253	New	+$63.8K	﹤0.01%	2878
2018 Q3	–	Sell	-76	Closed	-$31K	–	3025
2018 Q2	$31K	Sell	76 -24	-24%	-$11.4K	﹤0.01%	2858
2018 Q1	$54K	Hold	100	–	–	﹤0.01%	2820
2017 Q4	$59K	Buy	+100	New	+$46.5K	﹤0.01%	2849

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Russell Investments Group's PVLA Position: Q2 2026 in Review

Russell Investments Group increased its Palvella Therapeutics (PVLA) stake by 65% in Q2 2026, buying an estimated $1.07M and bringing the position to 22,345 shares worth $3.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1758.

Russell Investments Group first reported a position in PVLA in Q4 2017 and has held it in 12 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Russell Investments Group held 22,345 shares of Palvella Therapeutics worth $3.41M as of Q2 2026.
Russell Investments Group bought 8,818 Palvella Therapeutics shares in Q2 2026, an estimated $1.07M.
Palvella Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1758 holding.
Russell Investments Group first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 12 quarters since.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.